A Rapid and Sensitive Enzymatic Method for Epidermal Growth Factor Receptor Mutation Screening

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338

EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527

Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy

Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377

Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

Shepherd, F. A., Dancey, J. E., Ramlau, R., Mattson, K. V., Gralla, R. J., O’Rourke, M. A., Levitan, N. I., Gressot, L., Vincent, M. D., Burkes, R. L., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2095 · Cited by 2,178

Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome

Tsao, M., Sakurada, A., Cutz, J.-C., Zhu, C., Kamel‐Reid, S., Squire, J. A., Lorimer, I. A. J., Zhang, T., Liu, G., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,815

Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer

Cappuzzo, F., Hirsch, F. R., Rossi, E., Bartolini, S., Ceresoli, G. L., Bemis, L., Haney, J., Witta, S. E., Danenberg, K. D., Domenichini, I., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji112 · Cited by 1,538

Liquid Biopsies: Genotyping Circulating Tumor DNA

Diaz, L. A., & Bardelli, A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2011 · Cited by 2,210

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J.-S., Squire, J., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318290868f · Cited by 1,280

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC

Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.022 · Cited by 1,059

EGFR Mutations and Lung Cancer

Santos, G. D. C., Shepherd, F. A., & Tsao, M. (2011) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130206 · Cited by 964

Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors

Balak, M. N., Gong, Y., Riely, G. J., Somwar, R., Li, A. R., Zakowski, M. F., Chiang, A. C., Yang, G., Ouerfelli, O., Kris, M. G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1570 · Cited by 823

Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib

Jackman, D. M., Yeap, B. Y., Sequist, L. V., Lindeman, N., Holmes, A. J., Joshi, V. A., Bell, D. W., Huberman, M. S., Halmos, B., Rabin, M. S., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0462 · Cited by 584

BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations

Costa, D. B., Halmos, B., Kumar, A., Schumer, S., Huberman, M. S., Boggon, T. J., Tenen, D. G., & Kobayashi, S. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040315 · Cited by 511

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors

Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Đačić, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J., Squire, J. A., et al. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.03.001 · Cited by 461

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

Engelman, J. A., Mukohara, T., Zejnullahu, K., Lifshits, E., Borras, A. M., Gale, C.-M., Naumov, G. N., Yeap, B. Y., Jarrell, E., Sun, J., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28656 · Cited by 457

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Đačić, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J., Squire, J. A., et al. (2013) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0720-oa · Cited by 426

Epidermal Growth Factor Receptor Copy Number Alterations Correlate With Poor Clinical Outcome in Patients With Head and Neck Squamous Cancer

Temam, S., Kawaguchi, H., El‐Naggar, A. K., Jelı́nek, J., Tang, H., Liu, D. D., Lang, W., Issa, J. J., Lee, J. J., & Mao, L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.6605 · Cited by 402

Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non–Small-Cell Lung Cancer

Herbst, R. S., O’Neill, V., Fehrenbacher, L., Belani, C. P., Bonomi, P., Hart, L. L., Melnyk, O. O., Ramies, D. A., Lin, M., & Sandler, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3026 · Cited by 394

Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials

Jackman, D. M., Miller, V. A., Cioffredi, L., Yeap, B. Y., Janne, P. A., Riely, G. J., Ruiz, M. I. G., Giaccone, G., Sequist, L. V. D., & Johnson, B. E. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0888 · Cited by 377

Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing

Li, J., Wang, L., Mamon, H. J., Kulke, M. H., Berbeco, R. I., & Makrigiorgos, G. M. (2008) · Nature Medicine · doi:10.1038/nm1708 · Cited by 368

Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond

Ladanyi, M., & Pao, W. J. (2008) · Modern Pathology · doi:10.1038/modpathol.3801018 · Cited by 374

Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing

Thomas, R. K., Nickerson, E., Simons, J. F., Janne, P. A., Tengs, T., Yuza, Y., Garraway, L. A., LaFramboise, T., Lee, J. C., Shah, K., et al. (2006) · Nature Medicine · doi:10.1038/nm1437 · Cited by 360

Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer

Riely, G. J., Politi, K. A., Miller, V. A., & Pao, W. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0658 · Cited by 363

New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer

Oxnard, G. R., Arcila, M. E., Chmielecki, J., Ladanyi, M., Miller, V. A., & Pao, W. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2571 · Cited by 359

Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group

Oza, A. M., Elit, L. M., Tsao, M., Kamel‐Reid, S., Biagi, J. J., Provencher, D. M., Gotlieb, W. H., Hoskins, P. J., Ghatage, P., Tonkin, K. S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1578 · Cited by 344

Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response

Wu, J.-Y., Wu, S.-G., Yang, C.-H., Gow, C.-H., Chang, Y.-L., Yu, C.-J., Shih, J.-Y., & Yang, P.-C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5123 · Cited by 319

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.

Stewart, E., Tan, S. Z., Liu, G., & Tsao, M. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.11.06 · Cited by 314

Phase II Clinical Trial of Chemotherapy-Naïve Patients ≥ 70 Years of Age Treated With Erlotinib for Advanced Non–Small-Cell Lung Cancer

Jackman, D. M., Yeap, B. Y., Lindeman, N. I., Fidias, P., Rabin, M. S., Temel, J. S., Skarin, A. T., Meyerson, M. M., Tisch, A. H., Borras, A. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.5754 · Cited by 304

EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples

Ellison, G., Zhu, G., Moulis, A., Dearden, S., Speake, G., & McCormack, R. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-201194 · Cited by 301

A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

Wong, K.-K., Fracasso, P. M., Bukowski, R. M., Lynch, T. J., Münster, P. N., Shapiro, G. I., Janne, P. A., Eder, J. P., Naughton, M. J., Ellis, M. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1978 · Cited by 301

Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non–Small-Cell Lung Cancer Working Group: Standardization for Use in the Clinical Trial Setting

Eberhard, D. A., Giaccone, G., & Johnson, B. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.9858 · Cited by 302

Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib

Jackman, D. M., Holmes, A. J., Lindeman, N., Wen, P. Y., Kesari, S., Borras, A. M., Bailey, C., de Jong, F., Jänne, P. A., & Johnson, B. E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.6126 · Cited by 260

Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial

Janne, P. A., Wang, X., Socinski, M. A., Crawford, J., Stinchcombe, T. E., Gu, L., Capelletti, M., Edelman, M. J., Villalona-Calero, M. A., Kratzke, R. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.1315 · Cited by 245

Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer

Kuang, Y., Rogers, A. M., Yeap, B. Y., Wang, L., Makrigiorgos, M. G., Vetrand, K., Thiede, S., Distel, R. J., & Janne, P. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2592 · Cited by 232

The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group

Thunnissen, E., Kerr, K. M., Herth, F. J. F., Lantuéjoul, S., Papotti, M. G., Rintoul, R. C., Rossi, G., Skov, B. G., Weynand, B., Bubendorf, L., et al. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.10.017 · Cited by 228

EGFR Mutations in Lung Adenocarcinomas

Li, A. R., Chitale, D. A., Riely, G. J., Pao, W. J., Miller, V. A., Zakowski, M. F., Rusch, V. W., Kris, M. G., & Ladanyi, M. (2008) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2008.070178 · Cited by 214

Epidermal Growth Factor Receptor Mutation Testing in Lung Cancer: Searching for the Ideal Method

Pao, W. J., & Ladanyi, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1387 · Cited by 214

Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization–Positive/Phospho-Akt–Positive or Never Smoker Patients With Advanced Non–Small-Cell Lung Cancer: The ONCOBELL Trial

Cappuzzo, F., Ligorio, C., Janne, P. A., Toschi, L., Rossi, E., Trisolini, R., Paioli, D., Tisch, A. H., Magrini, E., Finocchiaro, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4300 · Cited by 210

High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies

Do, H., Krypuy, M., Mitchell, P. L. R., Fox, S. B., & Dobrovic, A. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-142 · Cited by 206

Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors

John, T., Liu, G., & Tsao, M. (2009) · Oncogene · doi:10.1038/onc.2009.197 · Cited by 211

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016

Tan, D. S. W., Yom, S. S., Tsao, M. S., Pass, H. I., Kelly, K., Peled, N., Yung, R. C., Wistuba, I. I., Yatabe, Y., Unger, M., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.008 · Cited by 201

Erlotinib for Frontline Treatment of Advanced Non–Small Cell Lung Cancer: a Phase II Study

Giaccone, G., Ruiz, M. I. G., Chevalier, T. L., Thatcher, N., Smit, E. F., Rodríguez, J. A., Janne, P. A., Oulid-Aïssa, D., & Soria, J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0260 · Cited by 199

Assessment of Epidermal Growth Factor Receptor Mutation by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration

Nakajima, T., Yasufuku, K., Suzuki, M., Hiroshima, K., Kubo, R., Mohammed, S., Miyagi, Y., Matsukuma, S., Sekine, Y., & Fujisawa, T. (2007) · CHEST Journal · doi:10.1378/chest.07-0095 · Cited by 198

Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors

Jänne, P. A., Boss, D. S., Camidge, D. R., Britten, C. D., Engelman, J. A., Garon, E. B., Guo, F., Wong, S., Liang, J., Letrent, S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1220 · Cited by 181

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients

Cappuzzo, F., Varella-Garcia, M., Finocchiaro, G., Skokan, M., Gajapathy, S., Carnaghi, C., Rimassa, L., Rossi, E., Ligorio, C., Di Tommaso, L., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604439 · Cited by 178

Noninvasive Saliva-based EGFR Gene Mutation Detection in Patients with Lung Cancer

Wei, F., Lin, C., Joon, A. Y., Feng, Z., Troche, G. E., Lira, M. E., Chia, D., Mao, M., Ho, C., Su, W., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201406-1003oc · Cited by 180

The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with EGFR Mutations

Heon, S., Yeap, B. Y., Lindeman, N. I., Joshi, V. A., Butaney, M., Britt, G. J., Costa, D. B., Rabin, M. S., Jackman, D. M., & Johnson, B. E. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0357 · Cited by 176

Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients

Koivunen, J. P., Kim, J., Lee, J., Rogers, A. M., Park, J. O., Zhao, X., Naoki, K., Okamoto, I., Nakagawa, K., Yeap, B. Y., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604469 · Cited by 168

Single Nucleotide Polymorphisms, Apoptosis, and the Development of Severe Late Adverse Effects After Radiotherapy

Azria, D., Özşahin, M., Kramar, A., Peters, S., Atencio, D. P., Crompton, N. E. A., Mornex, F., Pèlegrin, A., Dubois, J., Mirimanoff, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0700 · Cited by 154

Intratumoral Heterogeneity in EGFR -Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition

Soucheray, M., Capelletti, M., Pulido, I., Kuang, Y., Paweletz, C. P., Becker, J. H., Kikuchi, E., Xu, C., Patel, T. B., Al‐Shahrour, F., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0377 · Cited by 157

Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors

Jänne, P. A., & Johnson, B. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0555 · Cited by 147

EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer

van Zandwijk, N., Mathy, A., Boerrigter, L., Ruijter, H. J., Tielen, I. H. G., de Jong, D., Baas, P., Burgers, S. A., & Nederlof, P. M. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl323 · Cited by 147

Chemoradiotherapy and Gefitinib in Stage III Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor and KRAS Mutation Analysis: Cancer and Leukemia Group B (CALEB) 30106, a CALGB-Stratified Phase II Trial

Ready, N., Janne, P. A., Bogart, J. A., DiPetrillo, T. A., Garst, J. L., Graziano, S. L., Gu, L., Wang, X., Green, M. R., & Vokes, E. E. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181eba657 · Cited by 146

Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung Cancer

Park, S. E., Tisch, A. H., Cho, E. Y., Shim, Y. M., Kim, J., Kim, H. S., Lee, J., Park, Y. H., Ahn, J. S., Park, K., et al. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181a94af4 · Cited by 145

Detection of EGFR Mutations in Archived Cytologic Specimens of Non-Small Cell Lung Cancer Using High-Resolution Melting Analysis

Nomoto, K., Tsuta, K., Takano, T., Fukui, T., Fukui, T., Yokozawa, K., Sakamoto, H., Yoshida, T., Maeshima, A. M., Shibata, T., et al. (2006) · American Journal of Clinical Pathology · doi:10.1309/n5pq-ngw2-qkmx-09x7 · Cited by 145

Detection of Androgen Receptor Mutations in Circulating Tumor Cells in Castration-Resistant Prostate Cancer

Jiang, Y., Palma, J. F., Agus, D. B., Wang, Y., & Gross, M. E. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.143297 · Cited by 132

Genetic Predictors of Adverse Radiotherapy Effects: The Gene-PARE project

Ho, A. Y., Atencio, D. P., Peters, S., Stock, R. G., Formenti, S. C., Cesaretti, J. A., Green, S., Haffty, B. G., Drumea, K. C., Leitzin, L., et al. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.03.006 · Cited by 132

Lung Adenocarcinoma with EGFR Amplification Has Distinct Clinicopathologic and Molecular Features in Never-Smokers

Sholl, L. M., Yeap, B. Y., Iafrate, A. J., Tisch, A. H., Chou, Y.-P., Wu, M., Goan, Y., Su, L., Benedettini, E., Yu, J. Q., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2477 · Cited by 122

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: Focus on epidermal growth factor receptor mutation testing and mutation-positive patients

Roengvoraphoj, M., Tsongalis, G. J., Dragnev, K. H., & Rigas, J. R. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.05.001 · Cited by 121

Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers

Yonesaka, K., Zejnullahu, K., Lindeman, N. I., Homes, A. J., Jackman, D. M., Zhao, F., Rogers, A. M., Johnson, B. E., & Janne, P. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0957 · Cited by 121

Identification of Recurrent FGFR3–TACC3 Fusion Oncogenes from Lung Adenocarcinoma

Capelletti, M., Dodge, M. E., Ercan, D., Hammerman, P. S., Park, S.-I., Kim, J., Sasaki, H., Jablons, D. M., Lipson, D., Young, L., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1337 · Cited by 115

A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells

Molina‐Vila, M. Á., Bertrán-Alamillo, J., Reguart, N., Tarón, M., Castellà, E., Llatjós, M., Costa, C., Mayo, C., Pradas, A., Queralt, C., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318189f579 · Cited by 112

Uncommon Epidermal Growth Factor Receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance

Massarelli, E., Johnson, F. M., Erickson, H. S., Wistuba, I. I., & Papadimitrakopoulou, V. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.01.018 · Cited by 110

Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping

Kim, H.-R., Lee, S. Y., Hyun, D.-S., Lee, M. K., Lee, H.-K., Choi, C., Yang, S. H., Kim, Y., Lee, Y. C., Kim, S. Y., et al. (2013) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-32-50 · Cited by 108

Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer

Soh, J., Toyooka, S., Aoe, K., Asano, H., Ichihara, S., Katayama, H., Hiraki, A., Kiura, K., Aoe, M., Sano, Y., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.22190 · Cited by 105

Laser Capture Microdissection and Protein Microarray Analysis of Human Non-small Cell Lung Cancer

VanMeter, A. J., Rodriguez, A. S., Bowman, E. D., Jen, J., Harris, C. C., Deng, J., Calvert, V. S., Silvestri, A., Fredolini, C., Chandhoke, V., et al. (2008) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m800204-mcp200 · Cited by 106

Epidermal Growth Factor Receptor Mutation Detection Using High-Resolution Melting Analysis Predicts Outcomes in Patients with Advanced Non–Small Cell Lung Cancer Treated with Gefitinib

Takano, T., Ohe, Y., Tsuta, K., Fukui, T., Sakamoto, H., Yoshida, T., Tateishi, U., Nokihara, H., Yamamoto, N., Sekine, I., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0627 · Cited by 103

A Comparison of EGFR Mutation Testing Methods in Lung Carcinoma: Direct Sequencing, Real-time PCR and Immunohistochemistry

Angulo, B., Conde, E., Suárez‐Gauthier, A., Plaza, C., Martínez, R., Redondo, P., Izquierdo, E., Rubio‐Viqueira, B., Paz-Ares, L. G., Hidalgo, M. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043842 · Cited by 101

Efficacy and Safety of Single-Agent Pertuzumab, a Human Epidermal Receptor Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer

Herbst, R. S., Davies, A. M., Natale, R. B., Dang, T. P., Schiller, J. H., Garland, L. L., Miller, V. A., Mendelson, D. S., den Abbeele, A. D. V., Melenevsky, Y. V., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0460 · Cited by 101

Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution

Li, K., Yang, M., Liang, N., & Li, S. (2017) · Oncology Reports · doi:10.3892/or.2017.5409 · Cited by 95

Ultra deep sequencing detects a low rate of mosaic mutations in tuberous sclerosis complex

Qin, W., Kozłowski, P., Taillon, B. E., Bouffard, P., Tisch, A. H., Janne, P. A., Camposano, S. E., Thiele, E. A., Franz, D. N., & Kwiatkowski, D. J. (2010) · Human Genetics · doi:10.1007/s00439-010-0801-z · Cited by 95

Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation

Lee, J. J.-K., Kim, T. M., Koh, Y., Lee, S., Kim, D., Jeon, Y.-K., Chung, D. H., Yang, S.-C., Kim, Y. T., Kim, Y.-W., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.04.012 · Cited by 91

Rapid Detection of Epidermal Growth Factor Receptor Mutations in Lung Cancer by the SMart-Amplification Process

Hoshi, K., Takakura, H., Mitani, Y., Tatsumi, K., Momiyama, N., Ichikawa, Y., Togo, S., Miyagi, T., Kawai, Y., Kogo, Y., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0509 · Cited by 90

Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma

Shimizu (2011) · Oncology Reports · doi:10.3892/or.2011.1182 · Cited by 88

Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours

Janne, P. A. (2008) · Lung Cancer · doi:10.1016/s0169-5002(08)70099-0 · Cited by 86

The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives

Takeda, M., Yoshida, S., Inoue, T., Sekido, Y., Hata, T., Hamabe, A., Ogino, T., Miyoshi, N., Uemura, M., Yamamoto, H., et al. (2025) · Cancers · doi:10.3390/cancers17030428 · Cited by 82

Error correction in gene synthesis technology

Ma, S., Saaem, I., & Tian, J. (2011) · Trends in biotechnology · doi:10.1016/j.tibtech.2011.10.002 · Cited by 82

Prospective Study of the Accuracy of EGFR Mutational Analysis by High-Resolution Melting Analysis in Small Samples Obtained from Patients with Non–Small Cell Lung Cancer

Fukui, T., Ohe, Y., Tsuta, K., Furuta, K., Sakamoto, H., Takano, T., Nokihara, H., Yamamoto, N., Sekine, I., Kunitoh, H., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5207 · Cited by 82

Sample features associated with success rates in population-based EGFR mutation testing

Shiau, C. J., Babwah, J. P., da Cunha Santos, G., Sykes, J. R., Boerner, S. L., Geddie, W. R., Leighl, N. B., Wei, C., Kamel-Reid, S., Hwang, D. M., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000196 · Cited by 78

Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): Study of a comprehensive panel of molecular markers

Tiseo, M., Rossi, G., Capelletti, M., Sartori, G., Spiritelli, E., Marchioni, A., Bozzetti, C., Palma, G. D., Lagrasta, C. A., Campanini, N., et al. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.04.021 · Cited by 76

EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection

Roy‐Chowdhuri, S., Xi, L., Pham, T. H.-T., Hanson, J. C., Rodriguez‐Canales, J., Berman, A. W., Rajan, A., Giaccone, G., Emmert‐Buck, M. R., Raffeld, M. A., et al. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.184 · Cited by 74

Detection of EGFR and KRAS mutations on trans-thoracic needle aspiration of lung nodules by high resolution melting analysis

Fassina, A., Gazziero, A., Zardo, D., Corradin, M., Aldighieri, E., & Rossi, G. P. (2009) · Journal of Clinical Pathology · doi:10.1136/jcp.2009.067587 · Cited by 72

EGFR and K‐ras Mutation Analysis in Non‐Small Cell Lung Cancer: Comparison of Paraffin Embedded versus Frozen Specimens

Ruiz, M. I. G., Floor, K., Rijmen, F., Grünberg, K., Rodríguez, J. A., & Giaccone, G. (2007) · Analytical Cellular Pathology · doi:10.1155/2007/568205 · Cited by 73

COLD-PCR: a new platform for highly improved mutation detection in cancer and genetic testing

Li, J., & Makrigiorgos, G. M. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370427 · Cited by 69

Novel method for genomic analysis ofPKD1andPKD2mutations in autosomal dominant polycystic kidney disease

Tan, Y.-C., Blumenfeld, J. D., Anghel, R., Donahue, S. L., Belenkaya, R., Balina, M., Parker, T. S., Levine, D. M., Leonard, D. G. B., & Rennert, H. (2008) · Human Mutation · doi:10.1002/humu.20842 · Cited by 66

Tissue Heterogeneity of EGFR Mutation in Lung Adenocarcinoma

Sakurada, A., Lara-Guerra, H., Liu, G., Shepherd, F. A., & Tsao, M. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318168be93 · Cited by 63

Cytology‐based gene mutation tests to predict response to anti‐epidermal growth factor receptor therapy: A review

Malapelle, U., Bellevicine, C., Zeppa, P., Palombini, L., & Troncone, G. (2010) · Diagnostic Cytopathology · doi:10.1002/dc.21512 · Cited by 64

Evaluation of denaturing high‐performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall‐cell lung cancer

Cohen, V., Agulnik, J. S., Jarry, J., Batist, G., Small, D. I., Kreisman, H., Tejada, N. A., Miller, W. H., & Chong, G. (2006) · Cancer · doi:10.1002/cncr.22331 · Cited by 61

Two-round coamplification at lower denaturation temperature-PCR (COLD-PCR)-based sanger sequencing identifies a novel spectrum of low-level mutations in lung adenocarcinoma

Li, J., Milbury, C. A., Li, C., & Makrigiorgos, G. M. (2009) · Human Mutation · doi:10.1002/humu.21112 · Cited by 58

Coamplification at Lower Denaturation Temperature-PCR Increases Mutation-Detection Selectivity of TaqMan-Based Real-Time PCR

Li, J., Wang, L., Janne, P. A., & Makrigiorgos, G. M. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.113381 · Cited by 57

Limited copy number - high resolution melting (LCN-HRM) enables the detection and identification by sequencing of low level mutations in cancer biopsies

Do, H., & Dobrovic, A. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-82 · Cited by 59

Activating Germline R776H Mutation in the Epidermal Growth Factor Receptor Associated With Lung Cancer With Squamous Differentiation

van Noesel, J., van der Ven, W. H., van Os, T. A. M., Kunst, P. W. A., Weegenaar, J., Reinten, R. J. A., Kancha, R. K., Duyster, J., & van Noesel, C. J. M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.1586 · Cited by 57

Delay of treatment change after objective progression on first‐line erlotinib in epidermal growth factor receptor‐mutant lung cancer

Lo, P. C., Dahlberg, S. E., Nishino, M., Johnson, B. E., Sequist, L. V. D., Jackman, D. M., Janne, P. A., & Oxnard, G. R. (2015) · Cancer · doi:10.1002/cncr.29397 · Cited by 54

Digital quantification of mutant DNA in cancer patients

Diehl, F., & Diaz, L. A. (2006) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328011a8e7 · Cited by 53

EGFR Assays in Lung Cancer

Đačić, S. (2008) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e31817bf5a9 · Cited by 53

Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer

Jakobsen, J. N., & Sørensen, J. B. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1791-9 · Cited by 52

Are There Any Ethnic Differences in Molecular Predictors of Erlotinib Efficacy in Advanced Non-Small Cell Lung Cancer?

Ahn, M., Park, B.-B., Ahn, J. S., Kim, S. W., Kim, H., Lee, J. S., Kang, J., Choi, Y., SONG, H. S., Park, S. H., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4608 · Cited by 50

Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer

Xu, N., Fang, W., Mu, L., Tang, Y., Gao, L., Ren, S., Cao, D., Zhou, L., Zhang, A., Liu, D., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6461 · Cited by 48

Mutation Detection of Epidermal Growth Factor Receptor and KRAS Genes Using the Smart Amplification Process Version 2 from Formalin-Fixed, Paraffin-Embedded Lung Cancer Tissue

Miyamae, Y., Shimizu, K., Mitani, Y., Araki, T., Kawai, Y., Baba, M., Kakegawa, S., Sugano, M., Kaira, K., Lezhava, A., et al. (2010) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2010.090105 · Cited by 43

Rapid screening for nuclear genes mutations in isolated respiratory chain complex I defects

Pagniez-Mammeri, H., Lombès, A., Brivet, M., de Baulny, H. O., Landrieu, P., Legrand, A., & Slama, A. (2009) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2008.12.003 · Cited by 43

Detection of Epidermal Growth Factor Receptor Variations by Partially Denaturing HPLC

Chin, T. M., Anuar, D., Soo, R. A., Salto‐Tellez, M., Li, W. Q., Ahmad, B., Lee, S. C., Goh, B. C., Kawakami, K., Segal, A., et al. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2006.074831 · Cited by 42

A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations

Deng, H., Lei, Q., Wang, C., Wang, Z., Chen, H., Wang, G., Yang, N. Y., Huang, D. A., Yu, Q., Yao, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34627-5 · Cited by 40

Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients

Ruiz, M. I. G., Floor, K., Steinberg, S. M., Grünberg, K., Thunnissen, E., Beliën, J. A. M., Meijer, G. A., Peters, G. J., Smit, E. F., Rodríguez, J. A., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604781 · Cited by 41

Identifying the determinants of response to MDM2 inhibition

Saiki, A. Y., Caenepeel, S. R., Cosgrove, E. J., Su, C., Boedigheimer, M. J., & Oliner, J. D. (2015) · Oncotarget · doi:10.18632/oncotarget.3116 · Cited by 39

Molecular Diagnostics of Lung Carcinomas

Đačić, S. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2010-0625-rair.1 · Cited by 38

Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer

Lin, C., Huang, W.-L., Fang, W., Su, W., & Wong, D. T. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.1094379 · Cited by 37

Detection of clinically significant mutations in the epidermal growth factor receptor missed by direct sequencing using a highly sensitive DNA endonuclease

Borras, A. M., Kuang, Y., Rogers, A. M., Tisch, A. H., Ruiz, M. I. G., Joshi, V. A., Distel, R. J., Giaccone, G., Tarón, M., & Janne, P. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.10054

[Modified Restriction Enzyme-based Detection of EGFR Mutations in Lung Cancer].

Yang, F., Chen, K., Jiang, G., Li, J., & Wang, J. (2011) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2011.08.01

Development of A Simple Genotyping Method for Somatic Mutations of EGFR and Its Clinical Application

Ariyoshi, N., Iyoda, A., Hiroshima, K., Shibuya, K., Takiguchi, Y., Nakatani, Y., & Kitada, M. (2009) · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) · doi:10.5649/jjphcs.35.468

Screening of Epidermal Growth Factor Receptor Gene Mutation in Non-Small Cell Lung Cancer Using a PCR-Based Enzymatic Digestion Method

Jung, Y. J., Park, S. J., Lee, S. B., Kim, Y. T., Park, J.-Y., Park, I. K., Kang, C. H., & Kim, J. H. (2012) · Journal of Lung Cancer · doi:10.6058/jlc.2012.11.2.77

Detection of mutations in the EGFR tyrosine kinase domain by DNA sequencing

Silva, M. D., Flynn, K. E., Choppa, P., Zhou, Z., Bell, D. W., Iafrate, A. J., Paler, R. J., Allitto, B. A., & Rohlfs, E. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.10060